Get App
Last Updated : Sep 18, 2018 05:13 PM IST | Source:

Hold Aurobindo Pharma; target of Rs 630: Edelweiss

Edelweiss recommended hold rating on Aurobindo Pharma with a target price of Rs 630 in its research report dated May 29, 2018.

Broker Research @moneycontrolcom
  • bselive
  • nselive
Todays L/H

Edelweiss's research report on Aurobindo Pharma

Aurobindo Pharma (ARBP) reported muted Q4FY18 results. Adjusted PAT grew 5% YoY against our 16.5% expectation. The weak performance was due to product recall in injectables and erosion in key products like gRenvela. One‐time receivables securitization made in FY17 was not sustainable as gross debt grew to USD731mn (FY17: USD439mn) to fund increase an in working capital and the Generis acquisition.


Over FY18-20E, we estimate R&D cost to increase by ~80%, margin to decline ~270bps and earnings to remain almost flat. We maintain ‘HOLD/SP’ and cut TP to INR630 (15x FY20E EPS).


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Jun 5, 2018 06:01 pm
Follow us on
Available On